Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
MS

WKN: A3EKMY | ISIN: CNE100005RD2 | Ticker:
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
MABWELL SHANGHAI BIOSCIENCE CO LTD Chart 1 Jahr
5-Tage-Chart
MABWELL SHANGHAI BIOSCIENCE CO LTD 5-Tage-Chart

Aktuelle News zur MABWELL SHANGHAI BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.10.MABWELL-B 9M Loss Widens to RMB678M2
28.10.MABWELL-B (02493): OVERSEAS REGULATORY ANNOUNCEMENT - MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. 2026 THIRD QUARTERLY REPORT1
MABWELL SHANGHAI BIOSCIENCE Aktie jetzt für 0€ handeln
19.10.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL PRESENTATION OF CLINICAL DATA ON 9MW2821 AT THE 2026 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ...1
17.09.MABWELL-B (02493): ARTICLES OF ASSOCIATION1
17.09.MABWELL-B (02493): (1) POLL RESULTS OF THE 2026 FOURTH EXTRAORDINARY GENERAL MEETING; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION-
04.09.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING POSTER PRESENTATIONS OF UPDATED CLINICAL DATA FOR 9MW1911 AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) ...1
04.09.MABWELL-B (02493): 2026 INTERIM REPORT3
19.08.MABWELL-B (02493): DATE OF BOARD MEETING-
31.07.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA-
15.07.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA-
07.07.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA-
24.06.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA-
23.06.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF NMPA APPROVAL FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION-
18.06.MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL AND POSTER PRESENTATIONS OF THE LATEST CLINICAL DATA OF 9MW2821 AT THE 2026 ESMO CONGRESS ...1
18.06.MABWELL-B (02493): APPOINTMENT OF MEMBERS OF SENIOR MANAGEMENT1
18.06.MABWELL-B (02493): CHANGE OF AUTHORISED REPRESENTATIVE-
18.06.MABWELL-B (02493): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
18.06.MABWELL-B (02493): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR-
18.06.MABWELL-B (02493): RETIREMENT OF DIRECTORS ELECTION OF THE THIRD SESSION OF THE BOARD OF DIRECTORS ELECTION OF CHAIRMAN OF THE THIRD SESSION OF THE BOARD ...1
18.06.MABWELL-B (02493): POLL RESULTS OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING-
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1